Clear all data

SECRETARY OF THE SENATE

05 AUG 15 PM 3:59

Clerk of the House of Representatives	Secretary of the Senate
Legislative Resource Center	Office of Public Records
B-106 Cannon Building	232 Hart Building
Washington, DC 20515	Washington, DC 20510

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required to Complete This Page**

1. Registrant name

Novo Nordisk Inc.

2. Address ☒ Check if different than previously reported

500 New Jersey Avenue NW Suite 350

Washington DC 20001 USA

3. Principal place of business (if different than line 2)

Princeton NJ 08540 USA

City State/Zip or Country

4a. Contact Name b. Telephone number c. E-mail

Mr. Michael Mawby 202-626-4521 mmby@novonordisk.com

5. Senate ID # 284790-12

7. Client Name ☒ Self

Novo Nordisk Inc.

6. House ID # 36903000

00003728.68

TYPE OF REPORT 8. Year 2005 Midyear (January 1-June30) ☒ OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ ⇨ Termination Date _____ 11. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than $10,000 ☐

$10,000 or more ☐ ⇨ $ _____

Provide a good faith estimate, rounded to the nearest $20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting pe were:

Less than $10,000 ☐

$10,000 or more ☒ ⇨ $ 400,000

14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.

☒ **Method A.** Reporting amounts using LDA definitions only

☐ **Method B.** Reporting amounts under section 6033(b)(8) of tl Internal Revenue Code

☐ **Method C.** Reporting amounts under section 162(e) of the In Revenue Code

Edit >

Signature _____ Date _____

Printed Name and Title Michael Mawby, Chief Government Affairs Officer

LD-2DS (Rev 4/03)

Registrant Name Novo Nordisk Inc. Client Name Novo Nordisk Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the reg engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** p information as requested. Attach additional page(s) as needed.

15. General issue area code BUD - Budget/Appropriations (one per page)

16. Specific lobbying issues

FY 2005 Appropriations for HHS diabetes related activities including funding for National Diabetes Education Program and Diabetes Care Coalition.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

Senate
House
HHS
CDC, NIDDK

18. Name of each individual who acted as a lobbyist in this issue area

Name		Covered Official Position (if applicable)
Michael	Mawby	Chief Government Affairs Officer
Steve	McGill	Associate Director, Government Affairs
Peter	Norman	Senior Manager, Government Affairs
Christopher	McGowen	Manager, Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature _____ Date _____

Printed Name and Title Michael Mawby, Chief Government Affairs Officer

00000372869

Registrant Name Novo Nordisk Inc. Client Name Novo Nordisk Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the re engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code CPT - Copyright/Patent/Trademark (one per page)

16. Specific lobbying issues

H.R. 2795, Patent Reform Act of 2005; related patent, trademark and intellectual property issues.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

Senate
House

18. Name of each individual who acted as a lobbyist in this issue area

Name		Covered Official Position (if applicable)
Michael	Mawby	Chief Government Affairs Officer
Steve	McGill	Associate Director, Government Affairs
Peter	Norman	Senior Manager, Government Affairs
Christopher	McGowen	Manager, Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Printed Name and Title Michael Mawby, Chief Government Affairs Officer

00000372870

Registrant Name Novo Nordisk Inc. Client Name Novo Nordisk Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the re engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code HCR - Health Issues (one per page)

16. Specific lobbying issues

To ensure the safety of drugs imported from abroad; to ensure the safety of any generic biologics that may eventually be approved for use in the U.S.; to improve the detection, treatment and care of people with diabetes.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

Senate
House
HHS, CMS, CDC, NIDDK

18. Name of each individual who acted as a lobbyist in this issue area

Name		Covered Official Position (if applicable)
Michael	Mawby	Chief Government Affairs Officer
Steve	McGill	Associate Director, Government Affairs
Peter	Norman	Senior Manager, Government Affairs
Christopher	McGowen	Manager, Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Printed Name and Title Michael Mawby, Chief Government Affairs Officer

00000372871

Registrant Name Novo Nordisk Inc. Client Name Novo Nordisk Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the re engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code HOM - Homeland Security (one per page)

16. Specific lobbying issues

S. 975 - Project BioShield II Act of 2005 - Support broadening the approach to the selection of CBRN countermeasures to include broadly applicable agents.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

Senate
House
HHS
DHS

18. Name of each individual who acted as a lobbyist in this issue area

Name		Covered Official Position (if applicable)
Michael	Mawby	Chief Government Affairs Officer
Steve	McGill	Associate Director, Government Affairs
Peter	Norman	Senior Manager, Government Affairs
Christopher	McGowen	Manager, Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Printed Name and Title Michael Mawby, Chief Government Affairs Officer

00000372872

Registrant Name Novo Nordisk Inc. Client Name Novo Nordisk Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the re engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code MMM - Medicare/Medicaid (one per page)

16. Specific lobbying issues

Urging CMS to promote as widely as possible the coverage of diabetes screening; promotion of the Welcome to Medicare Physical available to all Medicare beneficiaries in the first six months of enrollment; Regulations related to implementing each of the diabetes provisions of the Medicare Prescription Drug and Modernization Act of 2003 with a special emphasis on ensuring that the regulations pertaining to the definition of insulin delivery devices as a covered drug reflect the sense of Congress as embodied in the conference report.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

Senate
House
HHS, CMC, CDC, NIDDK

18. Name of each individual who acted as a lobbyist in this issue area

Name		Covered Official Position (if applicable)
Michael	Mawby	Chief Government Affairs Officer
Steve	McGill	Associate Director, Government Affairs
Peter	Norman	Senior Manager, Government Affairs
Christopher	McGowen	Manager, Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Printed Name and Title Michael Mawby, Chief Government Affairs Officer

00000372873

Registrant Name Novo Nordisk Inc. Client Name Novo Nordisk Inc.

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

City State/Zip

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

Peter Norman

ISSUE UPDATE

24. General lobbying issues that **no longer** pertain

TAX

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal place of Business (city and state or country)
McKenna Long & Aldridge, LLP	1900 K Street NW #100 Washington DC 20006 USA	Washington DC USA
Podesta Mattoon	1001 G Street, NW, Suite 900 East Washington DC 20001 USA	Washington DC USA

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Ownershi percentag client

28. Name of each previously reported foreign entity that **no longer** owns, **or** controls, **or** is affiliated with the registrant, clier affiliated organization

Signature Michael Mawby Date 8/15/05

Printed Name and Title Michael Mawby, Chief Government Affairs Officer

LD2DS (REV 4/03)

00000372874